Vinva Investment Management Ltd Increases Stock Holdings in Pfizer Inc. $PFE

Vinva Investment Management Ltd raised its holdings in Pfizer Inc. (NYSE:PFE) by 22.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 478,174 shares of the biopharmaceutical company’s stock after buying an additional 87,685 shares during the quarter. Vinva Investment Management Ltd’s holdings in Pfizer were worth $11,404,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer in the 3rd quarter worth approximately $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the second quarter worth $30,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at $32,000. Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer in the 2nd quarter valued at $33,000. Finally, True Wealth Design LLC raised its stake in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.7%

Shares of PFE opened at $27.07 on Monday. The company has a market capitalization of $153.93 billion, a price-to-earnings ratio of 19.90 and a beta of 0.47. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The stock’s 50-day moving average price is $26.30 and its 200-day moving average price is $25.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the business earned $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s dividend payout ratio is 126.47%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. UBS Group started coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. Morgan Stanley decreased their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. Finally, HSBC reissued a “buy” rating and set a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $28.05.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.